Oxytocin, 1953: A Physician’s Read on the First Synthetic Peptide Hormone
By Andres Zuleta, MD
The 1955 Nobel Prize in Chemistry is usually filed under organic chemistry. Read du Vigneaud's Nobel lecture and the 1954 obstetrics paper, and it is also one of the first clean examples of what we now call a bioequivalence test: a synthetic molecule, matched against the native hormone, in patients.
The synthesis
Du Vigneaud's group at Cornell University Medical College reported "an octapeptide amide with the hormonal activity of oxytocin" in J Am Chem Soc in October 1953, with the full paper in 1954; vasopressin followed in 1954. (The octapeptide count treats the two half-cystines as one cystine; today oxytocin is described as a nonapeptide.) The route was classical solution-phase chemistry, ending in sodium-in-liquid-ammonia deprotection and air oxidation to close the 20-membered disulfide ring. Yield of active material from the protected intermediate was 20 to 30 percent.
The comparison
Synthetic and natural oxytocin were matched on amino acid composition, optical rotation, partition coefficients, electrophoretic mobility, infrared and ultraviolet spectra, resin elution and crystalline flavianate. Then, with the Lying-In Hospital obstetric group (Nickerson, Bonsnes, Douglas; Am J Obstet Gynecol, May 1954), the two were compared in labor induction and milk ejection. About 1 microgram of either, given intravenously to recently parturient women, induced milk ejection in 20 to 30 seconds, and the synthetic product "could not be distinguished from the natural oxytocin in its action."
Where the limits were, and are
Purified oxytocin carried small pressor and antidiuretic activity (7 and 3 units per mg), confirmed with the synthetic hormone, an early reminder that the posterior pituitary peptides overlap. Clinically, oxytocin's short half-life and cold-chain requirement remain real constraints. On the behavioral side, Walum, Waldman and Young (Biol Psychiatry 2016) concluded that intranasal oxytocin studies are generally underpowered with a high probability that most findings are not true effects, and the largest pediatric trial (Sikich, NEJM 2021; 290 participants, 24 weeks) found no difference from placebo on social withdrawal.
What synthesis made possible
Synthesis turned hormones into design problems. Zaoral, Kolc and Sorm (1967) deaminated position 1 and substituted D-arginine at position 8 of vasopressin; Vávra et al. (Lancet, May 1968) reported prolonged antidiuresis with little pressor effect in diabetes insipidus. DDAVP nasal spray was FDA approved on February 21, 1978. In obstetrics, oxytocin remains the standard for postpartum hemorrhage prevention, and in the WHO CHAMPION trial (NEJM 2018; 29,645 women, 10 countries) heat-stable carbetocin was noninferior for blood loss of at least 500 mL or additional uterotonics (14.5 vs 14.4 percent), though noninferiority was not shown for blood loss of at least 1000 mL.
For patients
The practical points I share: skin-to-skin contact after birth is associated with more breastfeeding at one to four months (Cochrane 2016, RR 1.24, moderate-quality evidence), and any peptide marketed with a large claim should be asked for its trial in people, the standard du Vigneaud set in 1954.
For the patient-friendly version, read my post on the ThriveMed blog: The First Hormone Built by Chemists. Join Thrive Nation: https://thrivemed.ai/programs/human-health-os#thrive-nation
Sources: J Am Chem Soc 1953;75:4879-4880 and 1954;76:3115, 4751-4752; Am J Obstet Gynecol 1954;67:1028-1034; du Vigneaud Nobel lecture, Dec 12, 1955; Collect Czech Chem Commun 1967;32:1250-1257; Lancet 1968;1:948-952; Biol Psychiatry 2016;79:251-257; N Engl J Med 2018;379:743-752; N Engl J Med 2021;385:1462-1473; Cochrane Database Syst Rev 2016;11:CD003519. Educational only, not medical advice.